Markov model structure

Slides:

Advertisements

Similar presentations

Description of Each Study in the Cross Trial Safety Analysis Solomon SD, et al. Circulation 2008 [Epub Mar 31]

Advertisements

COURAGE Economic Results of the COURAGE Trial William S. Weintraub, MD Chief of Cardiology Christiana Care Health System Professor of Medicine, Thomas.

Type 2 diabetes and high blood pressure How explosive is the cocktail?

The Cost-Effectiveness of Computer-Assisted Navigation in Total Knee Arthroplasty by Erik J. Novak, Marc D. Silverstein, and Kevin J. Bozic J Bone Joint.

Analyses of Covariance Comparing k means adjusting for 1 or more other variables (covariates) Ho: u 1 = u 2 = u 3 (Adjusting for X) Combines ANOVA and.

Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.

The ACTIVE Investigators. N Engl J Med 2009 Apr 3 [Epub]

Mechanism of Action of Aspirin Carlo Patrono, et al, N Engl J Med 2005;353:

● The results of this study suggest that using the prognostic test to guide ACT decisions in NSCLC is cost-effective compared to a SoC approach according.

Rosuvastatin 10 mg n=2514 Placebo n= to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.

Alcohol and hospital admissions for injury and alcohol poisoning in West Sussex– a second order Monte Carlo simulation Ross Maconachie Public Health WSCC.

Date of download: 6/2/2016 From: New Protease Inhibitors for the Treatment of Chronic Hepatitis C: A Cost-Effectiveness Analysis Ann Intern Med. 2012;156(4):

Flow Diagram of the Trial Selection Process Jeffrey S. Berger et al, JAMA. 2006;295:

Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: Aspirin Therapy in Primary Cardiovascular Disease.

Date of download: 6/21/2016 From: Aspirin, Statins, or Both Drugs for the Primary Prevention of Coronary Heart Disease Events in Men: A Cost–Utility Analysis.

Date of download: 6/26/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Cost-Effectiveness of C-Reactive Protein Testing.

Date of download: 6/27/2016 From: Population Strategies to Decrease Sodium Intake and the Burden of Cardiovascular Disease: A Cost- Effectiveness Analysis.

Date of download: 7/5/2016 Copyright © 2016 American Medical Association. All rights reserved. From: The Bleeding Risk and Natural History of Idiopathic.

Date of download: 9/18/2016 From: Cost-Effectiveness of Distributing Naloxone to Heroin Users for Lay Overdose Reversal Ann Intern Med. 2013;158(1):1-9.

From: Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction.

Copyright © 2014 American Medical Association. All rights reserved.

Structure of Cis and Trans Fatty Acids

From: Cost-Effectiveness of Genotype-Guided and Dual Antiplatelet Therapies in Acute Coronary Syndrome Ann Intern Med. 2014;160(4): doi: /M

Copyright © 2011 American Medical Association. All rights reserved.

LEADER trial: Primary Outcome

For a copy of the poster:

Systematic Review Systematic review

From: Economic Savings Versus Health Losses: The Cost-Effectiveness of Generic Antiretroviral Therapy in the United States Ann Intern Med. 2013;158(2):84-92.

SOCRATES Trial design: Patients with acute ischemic stroke were randomized in a 1:1 fashion to receive either ticagrelor 180 mg load + 90 mg BID or aspirin.

Mechanical thrombectomy

Improving Chronic Care Management

by Anuj Shah, Anand Shewale, Corey J. Hayes, and Bradley C. Martin

Using the Coronary Artery Calcium Score to Guide Statin Therapy

Value in Health Regional Issues

Bart S. Ferket, MD, PhD, Jonathan M

US Preventive Services Task Force. Ann Intern Med 2009;150:

European Urology Oncology

A comparison of open and endovascular revascularization for chronic mesenteric ischemia in a clinical decision model Wouter Hogendoorn, MD, M.G. Myriam.

P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Value in Health Regional Issues

Nat. Rev. Cardiol. doi: /nrcardio

Tornado diagram of one-way deterministic sensitivity analysis.

Cystatin C levels and risk of death from all causes

Potential mechanisms whereby statins may reduce the risk of stroke

Adjusted relative risk for developing end-stage renal disease (ESRD) associated with blood-pressure level BP level (mm Hg) Adjusted relative risk 95%

Jordan B. King et al. JCHF 2016;4:

Relative risks of clinical events for primary and secondary prevention with selected drugs Thomas A Gaziano, et al. Lancet 2006; 368:

Inclusion Criteria for Patients with Multiple Atherothrombotic Risk Factors and for Those with Established Cardiovascular Disease Deepak L.Bhatt, et al,

Berger JS, et al. JAMA 2009;301:

Flow diagram for exclusions of trials identified RCT indicates randomized controlled trial Hulten E, et al. Arch Intern Med 2006;166:

Baseline Characteristics of the Subjects*

Women’s Health Study: Baseline Characteristics Part 1

Age-Standardized Rates of Death from Any Cause According to the Estimated GFR among 1,120,295 Ambulatory Adults Alan S.Go et al. N Engl J Med 2004; 351:

Anut Sakulsupsiri, MSc, Phantipa Sakthong, PhD, Win Winit-Watjana, PhD

Markov model scheme. Markov model scheme. Patients start (state 0) with uncomplicated PCI revascularisation; then cycle between health states until death.

Baseline Characteristics by hs-CRP

A Single Participant Exposed Twice to an Inflammatory Stimulus

Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost- effectiveness analysis Mark D. Schleinitz, MS, MD, J.Peter Weiss, MS,

The benefit of evolocumab treatment is consistent regardless of inflammation level HR %CI ARR 1.6% 1.8%

Cost-effectiveness plane for all PARTNER-B vs all ADVANCE and all PARTNER vs ADVANCE high risk comparisons with ICERs from five studies; dashed line represents.

Christian Madelaire et al. JCHF 2018;6:

Ticagrelor versus prasugrel; risk ratio with 95% CIs for the primary composite end point, primary composite end point in those undergoing PCI, myocardial.

Cost-Effectiveness of Web-Based Patient-Reported Outcome Surveillance in Patients With Lung Cancer Thibaut Lizée, MD, Ethan Basch, MD, MSc, Pierre Trémolières,

Flowchart of the process of study selection LAR indicates laboratory-defined aspirin resistance Jaapjan D. Snoep, et al. Arch Intern Med 2007;167:

Prasugrel versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Omar Abdul-Jawad Altisent et al. JCIN 2016;9:

Probabilistic sensitivity analysis.

Cost-effectiveness acceptability curves (CEAC) of tight control versus clinical management excluding (base case) and including absenteeism due to Crohn’s.

Prasugrel and ticagrelor versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial.

Summary of incremental cost-effectiveness ratio (ICERs) of rtPA therapy from the literature. Summary of incremental cost-effectiveness ratio (ICERs) of.

Presentation transcript:

Markov model structure Women begin in the healthy state and can transition to the other states in yearly cycles. Patients can progress to death from any state. GI indicates gastrointestinal; MI, myocardial infarction. Michael Pignone, et al. Arch Intern Med

Base Case Estimates and Ranges Used in Sensitivity Analyses* Michael Pignone, et al. Arch Intern Med

Variation in cost per QALY gained with aspirin compared with no treatment across the range of potential values for the relative risk of ischemic stroke Variation in cost per quality-adjusted life-year (QALY) gained with aspirin compared with no treatment (represented on the y-axis) across the range of potential values for the relative risk of ischemic stroke in those taking aspirin (represented on the x-axis). The vertical broken line represents the base case value. Costs are expressed in 2005 US dollars. Michael Pignone, et al. Arch Intern Med

Variation in cost per QALY gained with aspirin compared with no treatment across the range of potential values for the relative risk of myocardial infarction (MI) Variation in cost per quality-adjusted life-year (QALY) gained with aspirin compared with no treatment (represented on the y-axis) across the range of potential values for the relative risk of myocardial infarction (MI) in those taking aspirin (represented on the x-axis). The vertical broken line represents the base case value. Costs are expressed in 2005 US dollars. Michael Pignone, et al. Arch Intern Med

Variation in cost per QALY gained with aspirin compared with no treatment across the range of potential values for the excess risk of gastrointestinal bleeding Variation in cost per quality-adjusted life-year (QALY) gained with aspirin compared with no treatment (represented on the y-axis) across the range of potential values for the excess risk of gastrointestinal bleeding in those taking aspirin (represented on the x-axis). The vertical broken line represents the base case value. Costs are expressed in 2005 US dollars. Michael Pignone, et al. Arch Intern Med

Variation in cost per QALY gained with aspirin compared with no treatment across the range of potential values for the utility of taking aspirin Variation in cost per quality-adjusted life-year (QALY) gained with aspirin compared with no treatment (represented on the y-axis) across the range of potential values for the utility of taking aspirin (represented on the x-axis). The vertical broken line represents the base case value. Costs are expressed in 2005 US dollars. Michael Pignone, et al. Arch Intern Med

Probabilistic sensitivity analysis and cost-effectiveness acceptability curve. A, Results of the probabilistic sensitivity analysis for the base case of 65-year-old women at moderate cardiovascular risk Results of the probabilistic sensitivity analysis for the base case of 65-year-old women at moderate cardiovascular risk. Each dot represents 1 iteration of the model. The y-axis represents incremental costs of aspirin compared with no therapy. The x-axis represents net quality-adjusted life-years (QALYs) with aspirin compared with no therapy. The diagonal line represents a cost per QALY gained of $50 000 in quadrant Michael Pignone, et al. Arch Intern Med

Probabilistic sensitivity analysis and cost-effectiveness acceptability curve. Results of the probabilistic sensitivity analysis for the base case of 65-year-old women at moderate cardiovascular risk Results of the probabilistic sensitivity analysis for the base case of 65-year-old women at moderate cardiovascular risk. B - The y-axis represents the probability that the cost per QALY gained is less than or equal to the values listed on the x-axis. ICER indicates incremental cost-effectiveness ratio. Michael Pignone, et al. Arch Intern Med